A Twenty-years' Experience in Pituitary Disease: Identification of Prognostic Factors in Pituitary Tumors

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Pituitary tumors represent a heterogeneous group of neoplasms by histotype. The pituitary adenomas are the most frequent heteroformation, among those affecting the pituitary gland, followed by meningiomas, craniopharyngiomas, germosomes and tumours secondary, such as metastases and lymphomas. Since these conditions are considered rare, the data epidemiology and prognosis to predict the natural history of these diseases can not be considered conclusive. Pituitary adenomas are a useful model for epidemiology in the study of pathology pituitary. Over the past 20 years, several attempts have been made to identify unique prognostic factors, which predict the outcome of these pathologies, but without To arrive at a definitive classification. The purpose of this study aims to collect clinical, biochemical, morphological and pathological data on the retrospective and prospective cohort of over 1600 patients undergoing neurosurgical removal of pituitary tumors in the last 20 years, to develop a prognostic classification.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients underwent surgery for pituitary tumors;

• pathology diagnosis of pituitary tumors;

• patients older then 18 years at diagnosis of pituitary tumors;

• 2 years follow-up;

Locations
Other Locations
Italy
Fondazione Policlinico Gemelli IRCCS
RECRUITING
Rome
Contact Information
Primary
Francesco Doglietto, Prof
francesco.doglietto@policlinicogemelli.it
+390630155701
Backup
Sabrina Chiloiro, MD
sabrina.chiloiro@policlinicogemelli.it
Time Frame
Start Date: 2025-03-10
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 1600
Treatments
Patients with pituitary tumors
Patients with pituitary tumors, underwent surgical resection
Sponsors
Leads: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

This content was sourced from clinicaltrials.gov